Each share of common stock is being offered together with a warrant to purchase one share of common stock at an exercise price of $2.08 per share, which price represents the greater of the book or market value of the stock on the date the definitive agreements were executed (subject to customary adjustments as set forth in the warrants).
The gross proceeds from the offering are expected to be approximately $950,000, prior to offering expenses payable by the Company. The Company intends to use the net proceeds received from the sale of the Securities to fund manufacturing of THIO for Phase II clinical trials and for working capital.
Reported Earlier, MAIA Biotechnology Raises $950k In Private Placement Of 507,364 Common Shares At $1.872/Share
以前に報告されたように、MAIA バイオテクノロジーは、507,364 株の普通株を1株1.872ドルで非公募発行し、95万ドルを調達しました
注目ニュース
更新日時